Orlynvah
Evidence Grade A — Regulatory approved. 56 published studies. 9 registered clinical trials.
Loading...
Sulopenem (sold as Orlynvah) is an oral antibiotic — not a peptide — approved specifically for uncomplicated urinary tract infections caused by bacteria resistant to commonly used antibiotics. It represents the first new oral antibiotic class for UTIs in decades and fills an important gap: giving patients with drug-resistant UTIs a tablet they can take at home rather than requiring hospital admission for intravenous antibiotics.
56 published studies: 30 human, 5 animal, 15 in-vitro, 13 reviews
Sulopenem (Orlynvah) is approved for uncomplicated UTIs caused by ciprofloxacin-nonsusceptible bacteria. The SURE-1 trial (1,671 patients) demonstrated superiority over ciprofloxacin in the resistant population (62.6% versus 36.0% success). It did not demonstrate non-inferiority to ciprofloxacin in susceptible infections or to intravenous ertapenem in complicated UTIs.
Sulopenem is not a peptide. Its clinical significance is providing an oral treatment option for drug-resistant UTIs that would otherwise require intravenous antibiotics and hospitalisation. Its narrow approved indication reflects its specific niche in the antimicrobial resistance landscape.
Sulopenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins — a mechanism shared with other beta-lactam antibiotics. Its key advantage is stability against the enzymes (AmpC and extended-spectrum beta-lactamases) that many resistant bacteria use to destroy conventional oral antibiotics. This allows oral treatment of infections that previously required intravenous hospital-based antibiotics.
The SURE-1 trial showed sulopenem was clearly superior to ciprofloxacin in patients with ciprofloxacin-resistant infections (63% success versus 36%). However, it did not match ciprofloxacin for susceptible infections, and a second trial (SURE-2) failed to show it could replace intravenous antibiotics for complicated UTIs. The narrow approved indication — uncomplicated UTIs in women with limited oral alternatives — reflects these mixed results. The regulatory pathway was complex, with an initial rejection in 2021 before eventual approval in October 2024. Despite the narrow label, sulopenem fills a genuine clinical need: antibiotic-resistant UTIs are increasingly common, and avoiding hospitalisation for IV antibiotics has both patient quality-of-life and cost benefits.
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
